177 related articles for article (PubMed ID: 30460997)
1. Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice.
Vermeer NS; Giezen TJ; Zastavnik S; Wolff-Holz E; Hidalgo-Simon A
Clin Pharmacol Ther; 2019 Apr; 105(4):962-969. PubMed ID: 30460997
[TBL] [Abstract][Full Text] [Related]
2. Identifiability of Biologicals: An Analysis Using EudraVigilance, the European Union's Database of Reports of Suspected Adverse Drug Reactions.
Correia Pinheiro L; Giezen TJ; Wolff-Holz E; Weise M; Laslop A; Hidalgo-Simon A
Clin Pharmacol Ther; 2021 Nov; 110(5):1311-1317. PubMed ID: 34472087
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of biological medicines as compared with non-biologicals: an analysis of the italian spontaneous reporting system database.
Cutroneo PM; Isgrò V; Russo A; Ientile V; Sottosanti L; Pimpinella G; Conforti A; Moretti U; Caputi AP; Trifirò G
Drug Saf; 2014 Nov; 37(11):961-70. PubMed ID: 25255847
[TBL] [Abstract][Full Text] [Related]
4. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
5. Is pharmacovigilance of biologicals cost-effective?
Claus B
Int J Clin Pharm; 2018 Aug; 40(4):787-789. PubMed ID: 30051230
[TBL] [Abstract][Full Text] [Related]
6. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
Felix T; Jordan JB; Akers C; Patel B; Drago D
Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
[TBL] [Abstract][Full Text] [Related]
7. Traceability of biologicals: present challenges in pharmacovigilance.
Vermeer NS; Spierings I; Mantel-Teeuwisse AK; Straus SM; Giezen TJ; Leufkens HG; Egberts TC; De Bruin ML
Expert Opin Drug Saf; 2015 Jan; 14(1):63-72. PubMed ID: 25369769
[TBL] [Abstract][Full Text] [Related]
8. EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies.
Francescon S; Fornasier G; Baldo P
Int J Clin Pharm; 2018 Aug; 40(4):778-782. PubMed ID: 30094558
[TBL] [Abstract][Full Text] [Related]
9. Biologicals and biosimilars: safety issues in Europe.
Portela MDCC; Sinogas C; Albuquerque de Almeida F; Baptista-Leite R; Castro-Caldas A
Expert Opin Biol Ther; 2017 Jul; 17(7):871-877. PubMed ID: 28540760
[TBL] [Abstract][Full Text] [Related]
10. The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK.
Klein K; Hazell L; Stolk P; Shakir S
Drug Saf; 2020 Mar; 43(3):255-263. PubMed ID: 31872358
[TBL] [Abstract][Full Text] [Related]
11. The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.
Vermeer NS; Ebbers HC; Straus SM; Leufkens HG; Egberts TC; De Bruin ML
Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):297-306. PubMed ID: 26676881
[TBL] [Abstract][Full Text] [Related]
12. Biopharmaceuticals safety perception in Slovakia: considerations and real-life pharmacovigilance data.
Lassanova M; Liskova S; Tisonova J; Fundarkova S; Lassan S
Bratisl Lek Listy; 2021; 122(7):443-448. PubMed ID: 34161110
[TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance of Biologics in a Multisource Environment.
Sagi S; Cohen HP; Woollett GR
J Manag Care Spec Pharm; 2017 Dec; 23(12):1249-1254. PubMed ID: 29172979
[TBL] [Abstract][Full Text] [Related]
14. [Biologicals and Biosimilars: Gaps in the Pharmacovigilance System in Portugal].
Portela MC; Sinogas C; Almeida FA; Baptista-Leite R; Castro-Caldas A
Acta Med Port; 2017 Mar; 30(3):205-212. PubMed ID: 28550830
[TBL] [Abstract][Full Text] [Related]
15. Traceability of biopharmaceuticals in spontaneous reporting systems: a cross-sectional study in the FDA Adverse Event Reporting System (FAERS) and EudraVigilance databases.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Domergue F; Egberts TC; Leufkens HG; De Bruin ML
Drug Saf; 2013 Aug; 36(8):617-25. PubMed ID: 23771794
[TBL] [Abstract][Full Text] [Related]
16. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
[TBL] [Abstract][Full Text] [Related]
17. Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland.
O'Callaghan J; Griffin BT; Morris JM; Bermingham M
BioDrugs; 2018 Jun; 32(3):267-280. PubMed ID: 29721705
[TBL] [Abstract][Full Text] [Related]
18. Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction.
Ingrasciotta Y; Cutroneo PM; Marcianò I; Giezen T; Atzeni F; Trifirò G
Drug Saf; 2018 Nov; 41(11):1013-1022. PubMed ID: 29796832
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
20. EU's new pharmacovigilance legislation: considerations for biosimilars.
Calvo B; Zuñiga L
Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
